Announcements Trials

Browse Landscape

Phase

Status

Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 26 Prostatic Neoplasms, Castration-Resistant 4 Prostatic Diseases 3 Neoplasm Metastasis 3 Metastatic Castration-resistant Prostate Cancer 3 Adenocarcinoma 3 Urogenital Neoplasms 2 Triple Negative Breast Neoplasms 2 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2 Male Urogenital Diseases 2 Genital Diseases, Male 2 Urogenital Diseases 1 Sleep Initiation and Maintenance Disorders 1 Prostate Cancer Metastatic 1 Non-metastatic Castration-resistant Prostate Cancer 1 Neoplasms by Site 1 Neoplasms 1 Metastatic Castration-resistant Prostate Neoplasms 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 High-Risk Localized Prostate Cancer 1 Fatigue 1 Depression 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Bulbo-Spinal Atrophy, X-Linked 1 Advanced Solid Tumor 1

Interventions

abiraterone 2 enzalutamide 1 darolutamide 1 bicalutamide 1 abemaciclib 1 Prednisolone 1 Docetaxel 1 AZD5305 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Bulbo-Spinal Atrophy, X-Linked × darolutamide × Clear all

NCT07190300 2026-06-03

TulmiSTAR-02

Novartis

Phase 1/2 Recruiting

Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon ⚡